Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel Free TAK Stock Alerts

Takeda Pharmaceutical (TAK) Stock Forecast & Price Target

Takeda Pharmaceutical logo
$15.19 +0.00 (+0.02%)
Closing price 06/2/2026 03:58 PM Eastern
Extended Trading
$14.88 -0.31 (-2.06%)
As of 08:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

Takeda Pharmaceutical - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy
Based on 4 Analyst Ratings
Sell
0
Hold
2
Buy
2

Based on 4 Wall Street analysts who have issued ratings for Takeda Pharmaceutical in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 4 analysts, 2 have given a hold rating, and 2 have given a buy rating for TAK.

Consensus Price Target

N/A

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for TAK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Takeda Pharmaceutical and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TAK Analyst Ratings Over Time

TypeCurrent Forecast
6/3/25 to 6/3/26		1 Month Ago
5/4/25 to 5/4/26		3 Months Ago
3/5/25 to 3/5/26		1 Year Ago
6/3/24 to 6/3/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price TargetN/AN/AN/AN/A
Forecasted UpsideN/AN/AN/AN/A
Consensus RatingModerate BuyModerate BuyHoldBuy

TAK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TAK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Takeda Pharmaceutical Stock vs. The Competition

TypeTakeda PharmaceuticalMedical CompaniesBroader Market
Consensus Rating Score
2.50
2.30
2.52
Consensus RatingModerate BuyHoldModerate Buy
Predicted UpsideN/A1,752.23% Upside15.37% Upside
News Sentiment Rating
Positive News

See Recent TAK News
Positive News
Positive News
Export
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
4/29/2026
Weiss Ratings logo
Weiss Ratings
Not Rated
 Reiterated RatingHold (C)
4/8/2026
Sanford C. Bernstein logo
Sanford C. Bernstein
4 of 5 stars
 UpgradeMarket Perform ➝ Outperform
3/3/2026
Zacks Research logo
Zacks Research
Not Rated
 UpgradeStrong Sell ➝ Hold
1/13/2026
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Initiated CoverageOverweight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 08:24 AM ET.


Should I Buy Takeda Pharmaceutical Stock? TAK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, June 1, 2026. Please send any questions or comments about these Takeda Pharmaceutical pros and cons to contact@marketbeat.com.

Takeda Pharmaceutical
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Takeda Pharmaceutical Company Limited:

  • Takeda is launching a new transformation program aimed at enhancing growth, which could lead to increased revenue and profitability in the coming years.
  • The company has a promising product pipeline, including TAK-881, a new formulation for primary immunodeficiency disease that could significantly improve patient treatment experiences.
  • Recent analyst ratings have been positive, with several brokerages upgrading their ratings, indicating growing confidence in the company's future performance.
  • The current stock price is around $30, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • Takeda expects to achieve substantial annualized gross savings by fiscal 2028, which could enhance its financial stability and allow for reinvestment in innovative projects.

Takeda Pharmaceutical
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Takeda Pharmaceutical Company Limited for these reasons:

  • The company is undergoing significant restructuring, which may lead to job losses and could impact employee morale and productivity in the short term.
  • There is uncertainty regarding the uptake of new products, which could affect revenue growth and overall financial performance.
  • Takeda has projected restructuring costs of JPY 170 billion this year, which could strain financial resources and impact profitability.
  • While the company has received positive ratings, the average rating remains a "Moderate Buy," suggesting that some analysts are cautious about its near-term prospects.
  • Investors may be concerned about the competitive landscape in the biopharmaceutical industry, which could pose challenges for Takeda's market position and growth potential.

TAK Forecast - Frequently Asked Questions

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TAK shares.

According to analysts, Takeda Pharmaceutical's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.

Over the previous 90 days, Takeda Pharmaceutical's stock had 1 upgrade by analysts.

Takeda Pharmaceutical has been rated by research analysts at Sanford C. Bernstein, and Weiss Ratings in the past 90 days.

Analysts like Takeda Pharmaceutical more than other "medical" companies. The consensus rating for Takeda Pharmaceutical is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how TAK compares to other companies.

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Takeda Pharmaceutical Recommendations


This page (NYSE:TAK) was last updated on 6/3/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel